A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease
Status:
Withdrawn
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this multi-centre, double blind-study is to evaluate the clinical
response of patients with moderate to severe Cohn's Disease (CD) following treatment with
different doses and dose regimens of Olokizumab, relative to placebo.